ERBB2 and colorectal carcinoma: Illustrating the benefit of such an approach, Randon and colleagues (59) demonstrated that more comprehensive negative selection of metastatic HER2+/RASwt CRC (including identification of ERBB2 co-alterations, other RTK/MAPK driver alterations, and/or ERBB2 copy number <6 by NGS) for treatment with dual HER2 blockade (trastuzumab plus either pertuzumab or a TKI) stratified patients according to clinical outcomes.